These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 15764713

  • 1. Human metabolism of the proteasome inhibitor bortezomib: identification of circulating metabolites.
    Pekol T, Daniels JS, Labutti J, Parsons I, Nix D, Baronas E, Hsieh F, Gan LS, Miwa G.
    Drug Metab Dispos; 2005 Jun; 33(6):771-7. PubMed ID: 15764713
    [Abstract] [Full Text] [Related]

  • 2. Oxidative deboronation of the peptide boronic acid proteasome inhibitor bortezomib: contributions from reactive oxygen species in this novel cytochrome P450 reaction.
    Labutti J, Parsons I, Huang R, Miwa G, Gan LS, Daniels JS.
    Chem Res Toxicol; 2006 Apr; 19(4):539-46. PubMed ID: 16608165
    [Abstract] [Full Text] [Related]

  • 3. Investigation of drug-drug interaction potential of bortezomib in vivo in female Sprague-Dawley rats and in vitro in human liver microsomes.
    Lu C, Gallegos R, Li P, Xia CQ, Pusalkar S, Uttamsingh V, Nix D, Miwa GT, Gan LS.
    Drug Metab Dispos; 2006 Apr; 34(4):702-8. PubMed ID: 16443666
    [Abstract] [Full Text] [Related]

  • 4. Synthesis, in vitro and in vivo biological evaluation, docking studies, and structure--activity relationship (SAR) discussion of dipeptidyl boronic acid proteasome inhibitors composed of beta-amino acids.
    Zhu Y, Zhu X, Wu G, Ma Y, Li Y, Zhao X, Yuan Y, Yang J, Yu S, Shao F, Li R, Ke Y, Lu A, Liu Z, Zhang L.
    J Med Chem; 2010 Mar 11; 53(5):1990-9. PubMed ID: 20158184
    [Abstract] [Full Text] [Related]

  • 5. Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma.
    Heider U, von Metzler I, Kaiser M, Rosche M, Sterz J, Rötzer S, Rademacher J, Jakob C, Fleissner C, Kuckelkorn U, Kloetzel PM, Sezer O.
    Eur J Haematol; 2008 Feb 11; 80(2):133-42. PubMed ID: 18005386
    [Abstract] [Full Text] [Related]

  • 6. Antitumor effects and drug interactions of the proteasome inhibitor bortezomib (PS341) in gastric cancer cells.
    Fujita T, Doihara H, Washio K, Ino H, Murakami M, Naito M, Shimizu N.
    Anticancer Drugs; 2007 Jul 11; 18(6):677-86. PubMed ID: 17762396
    [Abstract] [Full Text] [Related]

  • 7. Proteasome inhibition for treatment of multiple myeloma: clinical update.
    Stadtmauer EA.
    J Natl Compr Canc Netw; 2004 Nov 11; 2 Suppl 4():S10-5. PubMed ID: 19795531
    [Abstract] [Full Text] [Related]

  • 8. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
    Meister S, Schubert U, Neubert K, Herrmann K, Burger R, Gramatzki M, Hahn S, Schreiber S, Wilhelm S, Herrmann M, Jäck HM, Voll RE.
    Cancer Res; 2007 Feb 15; 67(4):1783-92. PubMed ID: 17308121
    [Abstract] [Full Text] [Related]

  • 9. The proteasome inhibitor bortezomib enhances the susceptibility to viral infection.
    Basler M, Lauer C, Beck U, Groettrup M.
    J Immunol; 2009 Nov 15; 183(10):6145-50. PubMed ID: 19841190
    [Abstract] [Full Text] [Related]

  • 10. Bortezomib: a novel therapy approved for multiple myeloma.
    Richardson PG, Anderson KC.
    Clin Adv Hematol Oncol; 2003 Oct 15; 1(10):596-600. PubMed ID: 16258456
    [Abstract] [Full Text] [Related]

  • 11. Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome.
    Groll M, Berkers CR, Ploegh HL, Ovaa H.
    Structure; 2006 Mar 15; 14(3):451-6. PubMed ID: 16531229
    [Abstract] [Full Text] [Related]

  • 12. BCL-2 family regulation by the 20S proteasome inhibitor bortezomib.
    Fennell DA, Chacko A, Mutti L.
    Oncogene; 2008 Feb 21; 27(9):1189-97. PubMed ID: 17828309
    [Abstract] [Full Text] [Related]

  • 13. Proteasome inhibition attenuates hepatic injury in the bile duct-ligated mouse.
    Anan A, Baskin-Bey ES, Isomoto H, Mott JL, Bronk SF, Albrecht JH, Gores GJ.
    Am J Physiol Gastrointest Liver Physiol; 2006 Oct 21; 291(4):G709-16. PubMed ID: 16798723
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
    Ludwig H, Khayat D, Giaccone G, Facon T.
    Cancer; 2005 Nov 01; 104(9):1794-807. PubMed ID: 16178003
    [Abstract] [Full Text] [Related]

  • 17. Proteasome inhibitors as therapeutics.
    Mitsiades CS, Mitsiades N, Hideshima T, Richardson PG, Anderson KC.
    Essays Biochem; 2005 Nov 01; 41():205-18. PubMed ID: 16250907
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Proteasome inhibition as a therapeutic strategy for hematologic malignancies.
    Mitsiades CS, Mitsiades N, Hideshima T, Richardson PG, Anderson KC.
    Expert Rev Anticancer Ther; 2005 Jun 01; 5(3):465-76. PubMed ID: 16001954
    [Abstract] [Full Text] [Related]

  • 20. Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy.
    Dick LR, Fleming PE.
    Drug Discov Today; 2010 Mar 01; 15(5-6):243-9. PubMed ID: 20116451
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.